As a leader in bio-integrative devices and a GMP manufacturer of biomaterials, Gel-Del is committed to creating devices and products for commercial use in many different and sometimes disparate markets. To support the Gel-Del mission and to further expand Gel-Del's Subsidiary Companies and their Product Portfolios, our business plan includes partnering and licensing agreements with other companies, including those already capable of bringing products to the marketplace. Business development at Gel-Del is actively seeking to identify, evaluate and pursue complementary business opportunities. We are interested in making agreements that bring businesses and product innovations together to create synergy and value through mutually beneficial partner relationships with companies, individuals, universities, and other entities.

We are actively engaged in using our broad platform technologies and complementary products in the following application areas: cardiovascular, drug delivery for oral-trans-mucosal, implant, trans-wound, and site-specific. Other areas include tissue culture, diagnostics, neuroscience, urological, orthopedic, cosmetic treatments, and other markets.

• Biomaterial Technology, hemo-compatible and non-thrombogenic surface modifications, for potential applications in a variety of areas, e.g., tissue fillers, stents, artificial blood vessels, catheters, site-specific drug delivery and more
• Drugs and biopharmaceuticals for use in drug/device combination products
• Tissue oriented particles, devices or medical products utilizing advanced biomaterials and/or site-specific drug release technology

Gel-Del® Technologies owns all of its Intellectual Property ("IP"). The Company has developed a broad and deep patent portfolio around its technology. The portfolio continues to expand. Gel-Del's first patent was issued January 29, 2002 (USPTO # 6342250). This patent covers the method of fabrication of the biomaterial and its use with drug and cell delivery. To protect its many products and applications, Gel-Del has 16 world (e.g., WO 01/87267) and U.S. patents pending and more in preparation. Gel-Del has focused its initial IP on tissue repair and drug delivery embodiments.